P
PRLD
Prelude Therapeutics Inc
4.805
-0.105-2.14%After Hours: 4.805 0.000 0.00%16:10 07/10 EDT
OPEN/PREV CLOSE4.920/4.910
TODAY RANGE4.350-4.980
VOL577.89K
MARKET CAP382.70M
52 WEEK RANGE0.7500-5.69
AVG VOL (3M)492.52K
% TURNOVER0.73%
TURNOVER--
P/E (TTM)-4.7935
% RANGE12.83%
EPS(TTM)-1.0024
P/E(FORWARD)-20.8913
P/B5.03
BVPS0.9550
DIVIDEND--
P/S24.92
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP212.15M
SHARES OUTSTANDING79.65M
NEXT EARNINGS08/12-08/17
FREE FLOAT44.15M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Benzinga·06/16 12:05
Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
TipRanks·06/10 20:39
Prelude Therapeutics Shareholders Back Leadership and Governance
Simply Wall St·05/16 14:20
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
TipRanks·05/15 09:13
Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Simply Wall St·05/13 22:50
Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives
TipRanks·05/12 12:04
Prelude Therapeutics Launches Phase 1 Trial and Extends Runway
Seeking Alpha·05/12 11:34
Prelude Therapeutics GAAP EPS of -$0.13 beats by $0.12, revenue of $4.58M
Reuters·05/12 11:13
Prelude Therapeutics Q1 net loss narrows as expenses fall
Dow Jones·05/12 11:02
*Prelude Therapeutics 1Q Rev $4.58M >PRLD
Dow Jones·05/12 11:02
*Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD
Dow Jones·05/12 11:01
*Prelude Therapeutics 1Q Loss $10.4M >PRLD
Dow Jones·05/04 14:08
Prelude Therapeutics Price Target Announced at $9.00/Share by D. Boral Capital
Dow Jones·05/04 14:08
Prelude Therapeutics Initiated at Buy by D. Boral Capital